LivaNova plc (NASDAQ: LIVN) reported Q1 EPS of $0.36, $0.21 better than the analyst estimate of $0.15. Revenue for the quarter came in at $247.6 million versus the consensus estimate of $232.3 million.

“Epilepsy sales growth in the quarter reflects improving market dynamics, especially in the United States. The pace of vaccination efforts, along with patients' and their caregivers' willingness to seek treatment, is key to the continued recovery of the Epilepsy business,” said Damien McDonald, Chief Executive Officer of LivaNova. “We expect the recovery to continue from here and develop into more consistent sales and EPS growth in the second half of the year. We remain focused on delivering growth in our core, achieving pipeline milestones and executing on initiatives to improve profitability and cash generation.”

GUIDANCE:

LivaNova plc sees FY2021 EPS of $1.40-$1.90, versus the consensus of $1.48.

LivaNova reaffirms its 2021 guidance, expecting worldwide net sales from continuing operations for the full year to grow between 8 and 13 percent on a constant-currency basis. Adjusted diluted earnings per share from continuing operations for 2021 are expected to be in the range of $1.40 to $1.90.

For earnings history and earnings-related data on LivaNova plc (LIVN) click here.